Drug Trial Radar · NCT04737486
A First-in-Human Study of AV-001 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Dec 16, 2020
Primary completion
Mar 10, 2021
Study completion Mar 10, 2021
Sponsor
- Lead sponsor
- Vasomune Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability assessments will be conducted, and blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) and pharmacodynamics (PD) analysis.
Conditions
- Covid19-associated ARDS
- Covid19
- ARDS
Interventions
AV-001Drug
AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
PlaceboOther
D-PBS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants experiencing drug-related adverse eventsTime frame: 8 days following a single intravenous dose (SAD) or 8 days following 7 consecutive daily intravenous doses (MAD)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.